Brief: IO Biotech Initiates Trial of IO102-IO103 in Combination With KEYTRUDA as First-Line Treatment in Multi-Arm Basket Trial
12/04/2022 13:42
April 12 (Reuters) - IO Biotech Inc IOBT.O :
* IO BIOTECH ANNOUNCES INITIATION OF PHASE 2 TRIAL OF
IO102-IO103
IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) AS FIRST-LINE
TREATMENT IN A MULTI-ARM BASKET TRIAL
Source text for Eikon: ID:nGNX6lB2Cv
Further company coverage: IOBT.O
((Reuters.Briefs@thomsonreuters.com;))